Immune-based therapies for cytomegalovirus infection

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Immune fitness is critical in the pathogenesis and outcome of cytomegalovirus (CMV) infection. CMV disease is seen almost exclusively among individuals with an immature or defective immune system, such as patients with AIDS, transplant recipients and the developing fetus. These observations have generated interest in immune-based strategies for the management of CMV disease. Among the immune-based therapies that have been investigated in experimental and clinical settings are: passive immunotherapy with immunoglobulin; CMV vaccination; adoptive CMV-specific T-cell immunotherapy; and immune reconstitution strategies (HAART in AIDS patients, and a reduction in pharmacologic immunosuppression among transplant recipients). However, except for immune reconstitution strategies, there is no widely accepted immune-based strategy that is proven to be highly effective for CMV disease management. The benefits of immunoglobulins remain debated in an era when antiviral therapy is widely available. CMV vaccination and adoptive immunotherapy, on the other hand, remain experimental, but have had encouraging preliminary results.

Original languageEnglish (US)
Pages (from-to)117-130
Number of pages14
JournalImmunotherapy
Volume2
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Cytomegalovirus Infections
Cytomegalovirus
Disease Management
Immunoglobulins
Vaccination
Acquired Immunodeficiency Syndrome
Therapeutics
Adoptive Immunotherapy
Passive Immunization
Highly Active Antiretroviral Therapy
Immunotherapy
Immunosuppression
Antiviral Agents
Immune System
Fetus
T-Lymphocytes

Keywords

  • Adoptive therapy
  • Cytomegalovirus
  • Immune reconstitution
  • Immunoglobulin
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Immune-based therapies for cytomegalovirus infection. / Razonable, Raymund R.

In: Immunotherapy, Vol. 2, No. 1, 01.2010, p. 117-130.

Research output: Contribution to journalArticle

@article{6656c5f4c2b040bbb82bb937fdfadb1e,
title = "Immune-based therapies for cytomegalovirus infection",
abstract = "Immune fitness is critical in the pathogenesis and outcome of cytomegalovirus (CMV) infection. CMV disease is seen almost exclusively among individuals with an immature or defective immune system, such as patients with AIDS, transplant recipients and the developing fetus. These observations have generated interest in immune-based strategies for the management of CMV disease. Among the immune-based therapies that have been investigated in experimental and clinical settings are: passive immunotherapy with immunoglobulin; CMV vaccination; adoptive CMV-specific T-cell immunotherapy; and immune reconstitution strategies (HAART in AIDS patients, and a reduction in pharmacologic immunosuppression among transplant recipients). However, except for immune reconstitution strategies, there is no widely accepted immune-based strategy that is proven to be highly effective for CMV disease management. The benefits of immunoglobulins remain debated in an era when antiviral therapy is widely available. CMV vaccination and adoptive immunotherapy, on the other hand, remain experimental, but have had encouraging preliminary results.",
keywords = "Adoptive therapy, Cytomegalovirus, Immune reconstitution, Immunoglobulin, Vaccine",
author = "Razonable, {Raymund R}",
year = "2010",
month = "1",
doi = "10.2217/imt.09.82",
language = "English (US)",
volume = "2",
pages = "117--130",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - Immune-based therapies for cytomegalovirus infection

AU - Razonable, Raymund R

PY - 2010/1

Y1 - 2010/1

N2 - Immune fitness is critical in the pathogenesis and outcome of cytomegalovirus (CMV) infection. CMV disease is seen almost exclusively among individuals with an immature or defective immune system, such as patients with AIDS, transplant recipients and the developing fetus. These observations have generated interest in immune-based strategies for the management of CMV disease. Among the immune-based therapies that have been investigated in experimental and clinical settings are: passive immunotherapy with immunoglobulin; CMV vaccination; adoptive CMV-specific T-cell immunotherapy; and immune reconstitution strategies (HAART in AIDS patients, and a reduction in pharmacologic immunosuppression among transplant recipients). However, except for immune reconstitution strategies, there is no widely accepted immune-based strategy that is proven to be highly effective for CMV disease management. The benefits of immunoglobulins remain debated in an era when antiviral therapy is widely available. CMV vaccination and adoptive immunotherapy, on the other hand, remain experimental, but have had encouraging preliminary results.

AB - Immune fitness is critical in the pathogenesis and outcome of cytomegalovirus (CMV) infection. CMV disease is seen almost exclusively among individuals with an immature or defective immune system, such as patients with AIDS, transplant recipients and the developing fetus. These observations have generated interest in immune-based strategies for the management of CMV disease. Among the immune-based therapies that have been investigated in experimental and clinical settings are: passive immunotherapy with immunoglobulin; CMV vaccination; adoptive CMV-specific T-cell immunotherapy; and immune reconstitution strategies (HAART in AIDS patients, and a reduction in pharmacologic immunosuppression among transplant recipients). However, except for immune reconstitution strategies, there is no widely accepted immune-based strategy that is proven to be highly effective for CMV disease management. The benefits of immunoglobulins remain debated in an era when antiviral therapy is widely available. CMV vaccination and adoptive immunotherapy, on the other hand, remain experimental, but have had encouraging preliminary results.

KW - Adoptive therapy

KW - Cytomegalovirus

KW - Immune reconstitution

KW - Immunoglobulin

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=77952653546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952653546&partnerID=8YFLogxK

U2 - 10.2217/imt.09.82

DO - 10.2217/imt.09.82

M3 - Article

C2 - 20635892

AN - SCOPUS:77952653546

VL - 2

SP - 117

EP - 130

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 1

ER -